UPDATE: Dougherty & Company Reiterates Buy Rating, Raises PT for Mednax

In a report released earlier today, Dougherty & Company LLC reiterated its Buy rating for Mednax, Inc. MD but dropped its price target from $100.00 to $80.00. Dougherty & Company said their decision “assumes investors will put an Enterprise Value on MD of approximately 8.0x our 2012 adjusted EBITDA forecast ($438 million). This seems reasonable in light of the company's leadership position, track record and growth prospects. In addition, it is lower than the multiple (10x) paid recently by a large, experienced private equity group to take Emergency Medical Services Corp. (EMS – NR) private. EMS is not a perfect comp for MD but it is as good a one as is available now.” Mednax, Inc. closed on Friday at $65.80.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetReiterationAnalyst RatingsDoughterty & Company
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!